News|Videos|March 31, 2026

Could Pluvicto Be a First-Line Systemic Treatment for Patients with Oligometastatic Hormone-Sensitive PCa?

Name: Could Pluvicto Be a First-Line Systemic Treatment for Patients with Oligometastatic Hormone-Sensitive PCa?
Uploaded: 2026-03-31T10:05:00Z
Duration: 10 min 35 s
Description: In a recent interview, James Nagarajah, M.D., discussed new phase 2 research demonstrating significantly delayed disease progression in a cohort of patients with oligometastatic hormone-sensitive prostate cancer treated with 177-Lu-PSMA-617 and complete remission in nearly a quarter of these patients.

Author(s)Jeff Hall

In a recent interview, James Nagarajah, M.D., discussed new phase 2 research demonstrating significantly delayed disease progression in a cohort of patients with oligometastatic hormone-sensitive prostate cancer treated with 177-Lu-PSMA-617 and complete remission in nearly a quarter of these patients.

New research suggests that the theranostic agent ¹⁷⁷Lu-PSMA-617 may provide a significant impact in treating oligometastatic hormone-sensitive prostate cancer (HSPC) and potentially deferring the use of androgen deprivation therapy (ADT).

Related to this article

October 20th, 2026

Can MRI-Based AI Have an Impact in Reducing Unnecessary Prostate Biopsies?

In a recent interview, Francesco Giganti, MD, PhD, discussed findings from a recent multicenter study demonstrating the ability of an AI software to provide significant clarity to initial PI-RADS 3 assessments on MRI and facilitate a nearly 19 percent reduction in unnecessary prostate biopsies.

October 14th, 2026

Molecular Imaging in Focus: Comparative PSMA PET Study Offers Insights for Men with Recurrent PCa and Low PSA Values

In a recent episode of our Molecular Imaging in Focus series, Jack Andrews, MD, discussed pertinent findings from a recent intra-patient comparative study of PSMA PET agents in men with recurrent prostate cancer presented at the recent ASTRO conference.

October 9th, 2026

What New Dosimetry Data Reveals About 177Lu-Edotreotide for GEP-NET Treatment

In a recent interview, Amir Iravani, MD, FRACP, discussed the radiotherapeutic agent 177Lu-edotreotide and new dosimetry data from the COMPETE trial that was recently presented at the ASTRO conference.

October 24th, 2026

Diagnostic Imaging's Weekly Scan: October 18 — October 24

Catch up on the top radiology content of the past week.

October 23rd, 2026

FDA Clears Machine Learning Module for Emerging Musculoskeletal Ultrasound Platform

Facilitating enhanced 3D visualization of skeletal anatomy, the BoneEnhance machine learning module reportedly provides automated segmentation of bone and surrounding tissues for the Accuro XV ultrasound system.

October 22nd, 2026

Could Photon-Counting CT Have an Impact as a Platform for Molecular Imaging?

Newly published preclinical research signals a substantial conceptual shift with a potential role of photon-counting CT in targeting specific biological processes.

October 21st, 2026

FDA Clears AI-Enabled FFR-IQ Software for Estimating Fractional Flow Reserve from CCTA

The FFR-IQ software recently demonstrated a 92.2 percent sensitivity for non-invasive estimation of fractional flow reserve (FFRC) based on coronary CT angiography (CCTA) scans.

October 20th, 2026

FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment

The NEXT-Cue AI software, which incorporates analysis of brain MRI scans, reportedly facilitates prognostic assessments of potential progression from mild cognitive impairment (MCI) to Alzheimer’s disease within five years.